ViaDerma Completes First Shipment of 500,000 Units to Nigeria
September 10, 2024 08:00 ET
|
ViaDerma, Inc.
LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a specialty pharmaceutical company known for developing innovative transdermal drug delivery systems, is pleased to...
Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid
September 05, 2024 06:30 ET
|
Merakris Therapeutics
Part 2 of the Phase II multicenter clinical study for the investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid, will begin late 2024.
Kane Biotech Announces new DispersinB® Publication in Pathogens and Conference Presentations
August 29, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the publication of a new review article on DispersinB® in the...
BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
August 29, 2024 07:00 ET
|
BioStem Technologies, Inc.
BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
Kane Biotech Announces Distribution Agreement with Qatar Datamation Systems for revyve™ Antimicrobial Wound Gel
August 28, 2024 08:40 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution...
Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve™ Antimicrobial Wound Gel
August 22, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution...
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of Care for Non-Healing Diabetic Foot Ulcers
August 21, 2024 07:00 ET
|
Biostem Technologies
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje®
Crescent Innovations reports strong interest in asset sale
August 13, 2024 08:30 ET
|
Crescent Innovations Inc.
Crescent Innovations Inc. reports that activity surrounding sale of its joint, bone and skin repair technology remains strong even at this late date.
ViaDerma Announces Shipment of 500,000 Units of its Flagship Product to Nigeria
August 13, 2024 08:00 ET
|
ViaDerma, Inc.
LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a leader in innovative wound care solutions, is excited to announce that a shipment of 500,000 units of its flagship...
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
August 12, 2024 16:14 ET
|
Biostem Technologies
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million